Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback